glucagon like peptide 1 glp 1 receptor agonist medications Glucagon-like peptide-1 Frontiers | Clinical perspectives on

Microencapsulated bitter compounds (from Gentiana lutea) reduce daily energy intakes in humans

Similarly, the evaluation of gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which occur frequently with GLP-1RAs (42) and have a major influence on the adherence to such treatment over time, have often been assessed in clinical trials solely via participant self-report, which is known to be unrelaible (eg, symptoms may not be volunteered due to embarrassment or poor recall) (43, 44)

It is unknown exactly who will be able to receive a retatrutide prescription this will only be determined when the FDA approves the drug

Research continues with other GLP-1 agents and in different patient populations

Women should not only rely on oral contraception in such a situation but either add a barrier contraception method for 4 weeks after initiation until four 4 weeks after the last dose escalation of tirzepatide or switch to a completely nonoral contraceptive method (61)